ABHD6 Inhibitors
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
WWL70 | 947669-91-2 | sc-222420 sc-222420A | 1 mg 5 mg | $54.00 $105.00 | ||
WWL70 is an alpha/beta-hydrolase domain 6 (ABHD6) inhibitor that selectively targets the enzyme′s active site, leading to reduced hydrolysis of 2-arachidonoylglycerol (2-AG) and thus enhancing endocannabinoid signaling that suppresses ABHD6′s functional activity. | ||||||
Betulinic Acid | 472-15-1 | sc-200132 sc-200132A | 25 mg 100 mg | $117.00 $344.00 | 3 | |
Betulinic Acid, a pentacyclic triterpenoid, indirectly inhibits ABHD6 by modulating lipid signaling pathways, leading to altered lipid environments that can disrupt ABHD6's enzymatic function on lipid substrates. | ||||||
Carbamazepine | 298-46-4 | sc-202518 sc-202518A | 1 g 5 g | $33.00 $71.00 | 5 | |
Carbamazepine, traditionally used as an anticonvulsant, can alter lipid bilayer properties, which may indirectly affect ABHD6's lipid interactions and subsequently its enzymatic activity due to changes in membrane dynamics. | ||||||
MAFP | 188404-10-6 | sc-203440 | 5 mg | $219.00 | 4 | |
MAFP inhibits serine hydrolases including ABHD6, thereby reducing the hydrolysis of 2-AG, which in turn enhances endocannabinoid signaling pathways, ultimately leading to decreased ABHD6-mediated signaling. | ||||||
JZL 195 | 1210004-12-8 | sc-279248 sc-279248A | 5 mg 10 mg | $83.00 $134.00 | ||
JZL195 serves as a dual inhibitor of FAAH and monoacylglycerol lipase (MAGL), indirectly increasing 2-AG levels and therefore diminishing ABHD6 activity by promoting endocannabinoid signaling pathways. | ||||||
Lipase Inhibitor, THL | 96829-58-2 | sc-203108 | 50 mg | $52.00 | 7 | |
THL is a serine hydrolase inhibitor that, while primarily targeting lipases involved in lipid digestion, can also inhibit ABHD6's activity on lipid substrates, consequently enhancing signaling pathways that reduce ABHD6 function. | ||||||
Rimonabant | 168273-06-1 | sc-205491 sc-205491A | 5 mg 10 mg | $73.00 $163.00 | 15 | |
Rimonabant, a cannabinoid receptor type 1 (CB1) antagonist, can indirectly modulate ABHD6 activity by influencing endocannabinoid signaling. Enhanced CB1 signaling leads to a feedback suppression of ABHD6 activity. | ||||||
AM-251 | 183232-66-8 | sc-200366A sc-200366 sc-200366B sc-200366C | 5 mg 10 mg 50 mg 100 mg | $72.00 $146.00 $624.00 $864.00 | 4 | |
AM251, similar to Rimonabant, is a CB1 antagonist that indirectly attenuates ABHD6 activity by modulating endocannabinoid system dynamics, which includes the functional regulation of ABHD6. | ||||||